Clinical Trial Update: Daclizumab to Treat Chronic Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of daclizumab for chronic immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Daclizumab (daclizumab)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Thrombocytopenia | Phase 2 | Status: COMPLETED